BMY

BMY

Bristol-Myers Squibb: Looks Like a Good Value

Eddy Elfenbein submits: Bristol-Myers Squibb (BMY) has popped up on my radar screen as a decent value. The company had a lousy third-quarter earnings report, but the one for the fourth-quarter was pretty good. I was also impressed by the company's forward guidance. Here’s a look at the stock (in blue, left scale), earnings-per-share (gold, right scale) and dividend (black, right scale). The graph is scaled at a ratio of 16-to-1 so when the blue and gold lines cross, the P/E Ratio is 16; when the blue and black lines cross, the dividend yield is 6.66%. Complete Story »

Bristol-Myers Reduces 2009 Outlook

Zacks.com submits:
Wednesday, Bristol-Myers Squibb (BMY) lowered its fiscal 2009 outlook as a result of the split-off of pediatric nutrition company Mead Johnson Nutrition Co (MJN). Bristol-Myers expects earnings per share from continuing operations in the range of $1.75 -$1.80, down from its earlier guidance of $2.00 - $2.05. Earlier, in Nov, Bristol-Myers decided to split off its 83.1% holding in Mead Johnson. Mead Johnson completed a public offering in Feb 2009. Since then, its shares have risen considerably. Following the completion of the spin-off, Bristol-Myers expects the transaction to be net cash flow positive to its biopharmaceutical business and accretive to earnings beginning in 2010. Earlier this month, the share swap ratio between the two companies was amended to 0.6313 shares of Mead Johnson per 1 Bristol-Myers common share from the earlier 0.6027. The offer expired on December 17. Complete Story »

5 Stocks that Give the Gift of Dividend Growth

Dividends4Life submits: Christmas is a time of giving. Families and loved-ones give gifts to each other. Many people give money to the needy and charities, while others give their time to help those that are not quite as fortunate. It seems that everyone is involved in giving this time of year, even corporations. Dividend growth stocks give a gift that keeps on giving – ever increasing dividends!Complete Story »

8 High-Quality Dividend Stocks

As markets normalize and investors begin to wade back into the water, traditional forms of investing will come back into the mainstream. Among the strategies to re-emerge will be growth and income oriented investment strategies. Unfortunately, income investors are now confronted with difficult choices. The U.S. treasury market appears increasingly risky as the government runs up massive debts, prints money and subsequent inflationary pressures increase. In addition, corporate bonds have experienced an unprecedented 6 month rally and are no longer as attractive as they were earlier this year when we were confronted with a once in a lifetime buying opportunity. In the equity markets we are confronted with a similar situation. Markets are coming off a massive rally and at current valuations are likely to return average or sub-par returns several years into the future. As investors search for income I believe dividend paying stocks will play a more and more important role in investor’s portfolios. In addition, portfolio managers are likely to begin diversifying out of higher risk corporate bonds and high beta assets in favor of lower volatility higher yielding assets. One of the obvious beneficiaries of such a theme is high quality dividend paying stocks. I’ve compiled a list of 8 examples below for readers to ponder and research. The goal was to create a list of very high quality high yielding, global names. The criteria were fairly straight forward: high ROE, low debt levels, high current ratio, strong free cash flows, and of course, a respectable dividend yield. The results are below. Thoughts, opinions and additions to the list are encouraged.Complete Story »

8 High-Quality Dividend Stocks

As markets normalize and investors begin to wade back into the water, traditional forms of investing will come back into the mainstream. Among the strategies to re-emerge will be growth and income oriented investment strategies. Unfortunately, income investors are now confronted with difficult choices. The U.S. treasury market appears increasingly risky as the government runs up massive debts, prints money and subsequent inflationary pressures increase. In addition, corporate bonds have experienced an unprecedented 6 month rally and are no longer as attractive as they were earlier this year when we were confronted with a once in a lifetime buying opportunity. In the equity markets we are confronted with a similar situation. Markets are coming off a massive rally and at current valuations are likely to return average or sub-par returns several years into the future. As investors search for income I believe dividend paying stocks will play a more and more important role in investor’s portfolios. In addition, portfolio managers are likely to begin diversifying out of higher risk corporate bonds and high beta assets in favor of lower volatility higher yielding assets. One of the obvious beneficiaries of such a theme is high quality dividend paying stocks. I’ve compiled a list of 8 examples below for readers to ponder and research. The goal was to create a list of very high quality high yielding, global names. The criteria were fairly straight forward: high ROE, low debt levels, high current ratio, strong free cash flows, and of course, a respectable dividend yield. The results are below. Thoughts, opinions and additions to the list are encouraged.Complete Story »

Astra-Zeneca Flies to JUPITER on Drug Results

The second phase of a monumental pharmaceutical study was released a few days ago, and women everywhere must pay attention. For those who believed the myth that cardiovascular disease was not significant in women, and that the use of statins wouldn’t help women who might be at risk – this is a big wake-up call. Pay attention: you are at risk and statins can be of enormous benefit. (And improper legislation may prevent women from having access to such a beneficial product).Complete Story »

Friday Options Recap

Frederic Ruffy submits: SentimentStocks rallied around surprising jobs numbers early Friday, but the rally ran out of gas midday and the major averages are holding only modest gains late in the trading session.The Dow Jones Industrial Average rose 150 points early after the Labor Department reported that the US economy lost just 11,000 jobs in November. The headline number was significantly better than the 120,000 loss economists were expecting. October numbers were revised to show a loss of 111,000 jobs, compared to an initial reading of -190,000. In addition, the unemployment rate fell to 10 percent, from 10.2 percent. Economists were looking for an increase to 10.3 percent.Complete Story »

Which Dividend Stocks Are Relatively Safe?

Hao Jin submits:The Fed is going to keep interest rates near zero for the foreseeable future. With 10 year treasury yields around 3.5%, solid blue chip companies offering decent dividends becomes popular. Not only do they offer current income and the possibility of capital gains, they also have better protection against inflation than regular bonds. No wonder Warren Buffett wrote “Buy American. I Am” article on The New York Times last October. (source: NY Times) However, the economy is still in the bottoming process. There is a potential risk for the economic to backslide. Which blue chips are relatively safe?Complete Story »

FDA Reviewing Bristol-Myers Squibb Biologic Transplant Drug

Zacks.com submits:
Last week, Bristol-Myers Squibb Company (BMY) announced the acceptance of a biologic license application (BLA) for belatacept by the U.S. Food and Drug Administration (FDA). The candidate is in late-stage development for treating kidney transplant patients. The agency has set May 1, 2010, as the Prescription Drug User Fee Act (PDUFA) action date.The biological product is being developed internally and is a fusion protein with novel immunosuppressive activity targeted to prevent solid organ transplant rejection. The company owns a patent covering belatacept as a composition of matter which expires in the U.S. in 2021.Complete Story »

Wall Street Breakfast: Must-Know News

  • Goldman is TARP-free at last. Goldman Sachs (GS) became the first major bank to completely shed its bailout ties, paying $1.1B to redeem the government's TARP warrants and calling the Treasury's valuation 'full and fair' given the government's support of the financial system. With the warrant redemption and the $318M Goldman paid in dividends on its $10B TARP aid, taxpayers received a 23% annualized return for the nine-month transaction.
  • S&P flip-flops on ratings. Standard & Poor's unexpectedly switched its rating of some bonds backed by commercial mortgages, upgrading the bonds to AAA just days after the same bonds had been sharply downgraded. The unusual move further damaged S&P's credibility and unsettled investors in the $700B market for commercial mortgage-backed securities [CMBS]. The reversal came after S&P realized bonds with a shorter lifespan were less risky than similarly structured bonds with a longer lifespan, a mistake that could reflect a basic misunderstanding of the way cash flows are distributed across CMBS.
  • Bristol-Myers buys biotech firm. Bristol-Myers Squibb (BMY) agreed to acquire Medarex (MEDX), the biotech firm it already owns a 2% stake in, for $2.4B in cash. Bristol-Myers said the $16/share deal, which marks a 90% premium to Medarex's closing price on Wednesday, buys it proven antibody discovery technology and rights to an immunotherapy the companies developed. MEDX +89% premarket (7:00 ET).
  • Intel fights antitrust fine. Intel (INTC) is fighting back against a record €1.06B ($1.45B) fine levied by EU antitrust regulators in May, saying the fine violates protections granted by European human rights law. Since the EU antitrust body handles both the investigation and judgment of a given case, companies don't have the opportunity to fully defend themselves as they would in a court. However, the appeal is a bit of a long shot as no EU antitrust appeal has ever won on this argument.
  • Amazon's shoe-in to online apparel. Amazon (AMZN) will buy online shoe retailer Zappos.com for around $928M, an aggressive expansion into online apparel after Amazon's solo attempts at selling footwear were unsuccessful. Zappos is known for its fiercely loyal customer base, good customer service and free shipping/free returns policy. AMZN +0.6% premarket (7:00 ET).
  • Bair wants large firms to pay. FDIC's Sheila Bair is scheduled to testify before the Senate Banking Committee this morning, and will ask lawmakers to impose fees on the country's biggest financial firms. Bair wants Congress to create an industry-supported Financial Company Resolution Fund which will provide working capital and cover unanticipated losses if the government has to wind down a failed firm. In addition to minimizing government outlays, this would also "provide an economic incentive for an institution not to grow too large."
  • SEC targets pay-to-play. The SEC voted unanimously to propose rules preventing investment advisers from managing public programs for two years if they make political contributions. The proposal is an attempt to curb pay-to-play practices, in which public contracts are awarded to those who make political contributions.
  • Chrysler warns on dealership legislation. Chrysler warned it could face liquidation for a second time if lawmakers move forward with a plan to reinstate terminated dealership agreements. The House of Representatives has already approved a measure to restore contracts with 789 dealerships, but the bill's future in the Senate is less certain.
  • Moody's rebuffed in Berkshire sale. Moody's (MCO) fell 10.3% in after-hours trading following a disclosure by Berkshire Hathaway (BRK.A) that it sold 7.99M shares of the ratings company this week. Though Berkshire remains Moody's largest shareholder, the sale reduced its stake by 17%. Moody's has reported a profit decline for seven consecutive quarters.
  • Porsche CEO, CFO resign. Porsche's CEO Wendelin Wiedeking and CFO Holger Haerter both resigned from the company with immediate effect, after coming to "the conclusion that the further strategic development of Porsche... is better off, if they are not on board as acting persons," said a company spokesman. The move is expected to facilitate a merger agreement with Volkswagen (VLKAY.PK).
  • eBay beats as Paypal, marketplace show signs of life. eBay (EBAY) managed to beat quarterly earnings expectations (see details below), even as profit fell 29% and revenue fell 4%. The company's PayPal online-payments unit continued to grow strongly and a decline in eBay's core marketplace leveled off.
  • ING may sell private banking unit. ING Group (ING) reportedly hired JPMorgan Chase (JPM) to advise it on the possible sale of its private banking business in Europe and Asia. A deal could be worth over $1B.
  • House prices rise. The FHFA House Price Index was up 0.9% in May vs. -0.2% consensus, after falling 0.3% in April (revised). Nationwide prices are down 5.6% from a year earlier, and 10.7% from the April 2007 peak.

Earnings: Thursday Before Open

  • Bunge (BG): Q2 EPS of $2.28 beats by $1.57. Revenue of $11B (-23.5%) vs. $12B. (PR)
  • Danaher (DHR): Q2 EPS of $0.89 beats by $0.01. Revenue of $2.7B (-19%) vs. $2.8B. (PR)
  • Diamond Offshore Drilling (DO): Q2 EPS of $2.79 beats by $0.15. Revenue of $946M (-0.8%) vs. $942M. (PR)
  • EnCana (ECA): Q2 EPS of $1.22 beats by $0.25. Revenue of $3.8B (-49%) vs. $4.4B. (EnCana news release (.pdf))
  • Ford Motor (F): Q2 EPS of -$0.21 beats by $0.27. Revenue of $27.2B (-34%) vs. $24.8B. (PR)
  • Goodrich (GR): Q2 EPS of $1.15 beats by $0.04. Revenue of $1.7B (-8%) in-line. (PR)
  • Newmont Mining (NEM): Q2 EPS of $0.43 misses by $0.04. Revenue of $1.6B (+7%) in-line. (PR)
  • NII Holdings (NIHD): Q2 EPS of $0.79 beats by $0.23. Revenue of $1.1B (-4%) vs. $1B. (PR)
  • PNC Financial Services Group (PNC): Q2 EPS of $0.14 vs. consensus of $0.45 (may not be comparable). Revenue of $4B (+95.5%) vs. $3.65B. (PR)
  • Potash Corp. (POT): Q2 EPS of $0.62 misses by $0.07. Revenue of $856M (-67%) vs. $981M. Issues downside Q3 EPS guidance of $0.80-1.20 vs. $1.56 consensus. Issues downside FY '09 EPS guidance of $4.00-5.00 vs. $5.24 consensus. Shares -2.3% premarket (6:50 ET). (PR)
  • Terra Industries (TRA): Q2 EPS of $0.81 misses by $0.10. Revenue of $453.5M (-46%) vs. $568M. (PR)
  • Thermo Fisher Scientific (TMO): Q2 EPS of $0.74 beats by $0.08. Revenue of $2.5B (-8%) vs. $2.4B. (PR)
  • Xerox (XRX): Q2 EPS of $0.16 beats by $0.05. Revenue of $3.7B (-18%) in-line. (PR)

Earnings: Wednesday After Close

  • Alliance Data Systems (ADS): Q2 EPS of $0.95 misses by $0.07. Revenue of $460M (-9%) vs. $481M. Sees Q3 EPS of $1.34 in-line. Maintains 2009 EPS guidance of $5.15 vs. $5.00. (PR)
  • Amdocs (DOX): Q3 EPS of $0.53 beats by $0.05. Revenue of $690M (-16%) vs. $679M. Sees Q4 EPS of $0.47-0.51 vs. $0.48. Sees Q4 revenue of $670M-690M vs. $668M. (PR)
  • Citrix Systems (CTXS): Q2 EPS of $0.39 beats by $0.01. Revenue of $393M (+0%) vs. $387M. Sees Q3, FY09 revenues flat vs. 2008. (PR)
  • Covanta Holding Corp. (CVA): Q2 EPS of $0.21 beats by $0.01. Revenue of $376M (-11%) vs. $391M. Reaffirms 2009 EPS $0.65-0.80 vs. $0.71 and adjusted EBITDA of $500M-540M. (PR)
  • C.R. Bard (BCR): Q2 EPS of $1.23 beats by $0.02. Revenue of $625M (+1%) vs. $634M. (PR)
  • eBay (EBAY): Q2 EPS of $0.37 beats by $0.01. Revenue of $2.1B (-4%) vs. $2B. Sees Q3 EPS of $0.34-0.36 vs. $0.35. Sees Q3 revenue of $2.05B-2.15B vs. $2B. (PR)
  • Equifax (EFX): Q2 EPS of $0.57 in-line. Revenue of $455M (-9%) vs. $453M. Sees Q3 EPS of $0.52-0.57 vs. $0.59. (PR)
  • Equinix (EQIX): Q2 EPS of $0.44 beats by $0.11. Revenue of $213M (+7%) vs. $209M. Sees Q3 revenue of $221M-225M vs. $220M. Sees FY09 revenue of $860M-$875M vs. $861M. (PR)
  • E*TRADE Financial (ETFC): Q2 EPS of -$0.22 beats by $0.09. Total loan loss allowance was flat at $1.2B, or 5% of gross loans receivable. (PR)

Complete Story »

Syndicate content